Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

TEXAS PAIN RELIEF GROUP PLLC

NPI: 1003246299 · HURST, TX 76054 · Pain Medicine (Physical Medicine & Rehabilitation) Physician · NPI assigned 11/25/2013

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official GARI, TRACIE controls 12+ related entities in our dataset. Read more

$507K
Total Medicaid Paid
21,503
Total Claims
19,722
Beneficiaries
25
Codes Billed
2020-03
First Month
2024-12
Last Month

Provider Details

Authorized OfficialGARI, TRACIE (CHIEF ADMINISTRATIVE OFFICER)
NPI Enumeration Date11/25/2013

Related Entities

Other providers sharing the same authorized official: GARI, TRACIE

ProviderCityStateTotal Paid
CHARLES K FRIEDMAN DO PA ST PETERSBURG FL $2.96M
WEST PARK SURGERY CENTER LLC PINELLAS PARK FL $2.37M
FLORIDA PAIN RELIEF GROUP PLLC TAMPA FL $1.90M
MEDICAL TOX LABS, LLC TAMPA FL $655K
PHYSICIAN PARTNERS OF AMERICA CRNA OPERATIONS LLC HURST TX $349K
MEDHAT F. MIKHAEL, M.D., INC FOUNTAIN VALLEY CA $341K
SUN CITY CENTER AMBULATORY SURGERY CENTER, LLC RUSKIN FL $274K
MEDICAL DNA LABS, LLC TAMPA FL $107K
RICHARD L SMITH MD PA ORLANDO FL $74K
MERRITT ISLAND OUTPATIENT SURGERY CENTER, LLC MERRITT ISLAND FL $15K
HURST AMBULATORY SURGERY CENTER, LLC HURST TX $275.62
PAIN INSTITUTE OF TAMPA BAY, PLC TAMPA FL $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 1,091 $1K
2021 3,288 $34K
2022 5,464 $128K
2023 6,560 $194K
2024 5,100 $149K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 11,229 10,038 $263K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,736 3,539 $76K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 3,842 3,532 $73K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 510 477 $47K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 540 517 $28K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 128 125 $5K
99215 Prolong outpt/office vis 32 32 $2K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 34 33 $2K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 54 52 $2K
83992 161 158 $1K
99205 Prolong outpt/office vis 13 13 $1K
80356 162 159 $961.00
80324 162 159 $916.05
80369 151 148 $750.24
80353 162 159 $737.80
80360 159 156 $642.96
80359 161 158 $608.30
80361 72 72 $477.36
80365 75 75 $414.75
80362 60 60 $322.80
80348 12 12 $76.56
80346 12 12 $75.36
80354 12 12 $71.40
80358 12 12 $61.44
80373 12 12 $57.60